Nieuroselektywne i uroselektywne leki α1-adrenolityczne u szczególnie wymagających pacjentów w praktyce urologicznej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2020
Słowa kluczowe:
doksazosyna, tamsulozyna, LUTS, BPH, nadciśnienie tętnicze, jakość życia, compliance
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leki α1-adrenolityczne to szeroka grupa substancji, w ramach której możliwy jest optymalny dobór terapii dla różnych pacjentów z dolegliwościami ze strony dolnych dróg moczowych. Ponieważ nie ma jednego uniwersalnego leku dla wszystkich, należy jak najlepiej wykorzystać silne strony danej substancji. W niniejszej pracy porównano uroselektywny lek α1-adrenolityczny z lekiem nieuroselektywnym (tamsulozynę z doksazosyną).
##plugins.themes.bootstrap3.article.details##
Jak cytować
Hanecki, R. (2020). Nieuroselektywne i uroselektywne leki α1-adrenolityczne u szczególnie wymagających pacjentów w praktyce urologicznej. Medycyna Faktów , 13(4(49), 467-472. https://doi.org/10.24292/01.MF.0420.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Puente J, Sweeney M, Walmsley P et al. Blood pressure effects of doxazosin in the gastrointestinal therapeutic system formulation in hypertensive and normotensive patients with benign prostatic hyperplasia. Eur Heart J. 1998; 19(suppl): abst P1128.
2. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000; 283: 1967-75.
3. Talseth T, Westlie L, Daae L. Doxazosin nand atenolol as monotherapy on mild and moderate hypertension: a randomized parallel study with a three-year follow up. Am Heart J. 1991; 121(suppl): 280-5.
4. Giorda C, Appendina M, Mason MG et al. Alpha1-blocker doxazosin inproves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism. 1995; 44: 673-6.
5. Ramsay LE, Williams B, Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999; 13: 569-92.
6. Maruenda J, Bhatnagar V, Lowenthal DT. Hypertension in the elderly with coexisting benign prostatic hyperplasia. Urology. 1999; 53(suppl 3a): 7-13.
7. Cybulska B, Szostak WB. Postępowanie w zaburzeniach lipidowych u chorego na nadciśnienie tętnicze. Przewodnik Lekarza. 2003; 1: 82-93.
8. Januszewicz W, Prejbisz A. Leczenie nadciśnienia tętniczego u chorych ze współistniejącymi zaburzeniami metabolicznymi. Nefrol Nadciśn Tętn. 2005.
9. Poulter N, Williams B. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Am J Hypertens. 2001; 14: 1170-2.
10. Ferrara La, di Marino L, Russo O et al. Doxazosin and Captopril in Mildly Hypercholesterolemic Hypertensive Patients – The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; (21): 97-104.
11. Borgsteede S, Bruggeman R, Hoefnagel R et al. Tamsulosin and hyperglycaemia in patients with diabetes. Neth J Med. 2010; 68(3): 141-3.
12. Hutchinson DS, Bengtsson T. Alpha1A-adrenoceptors activate glucose uptake in L6 muscle cells through a phospholipase C-, phosphatidylinositol- 3 kinase-, and atypical protein kinase C-dependent pathway. Endocrinol. 2005; 146(2): 901-12.
13. Cheng JT, Liu IM, Yen ST et al. Role of alpha1A-adrenoceptor in the regulation of glucose uptake into white adipocyte of rats in vitro. Auton Neurosci. 2000; 84(3): 140-6.
14. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int. 2003; 91: 41-4.
15. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005; 31: 664-73.
16. Irini P, Chatziralli MD, Theodoros N et al. Risk Factors for Intraoperative Floppy Iris Syndrome: a Meta-Analysis. Ophthalmology. 2011; 118: 730-5.
17. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97(2): 34-8.
18. Lepor H; for the Tamsulosin Investigator Group. Phase III multicenter placebo‐controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998; 51: 892-900.
19. Lepor H; for the Tamsulosin Investigator Group. Long‐term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled double‐blind extension of phase III trial. Urology. 1998; 51: 901-6.
20. Narayan P, Lepor H. Long‐term open‐label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001; 57: 466-70.
21. Chung MS, Lee SH, Parket KK et al. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. Int J Clin Pract. 2011; 65(11): 1193-9.
22. Zhang K, Yu W, Jin J et al. Effect of Doxazosin Gastrointestinal Therapeutic System 4 mg vs Tamsulosin 0.2 mg Nocturia in Chinese Men With Lower Urinary Tract Symptoms: a Prospective, Multicenter, Randomized, Open, Parallel Study. Urology. 2011; 78(3): 636-40.
2. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000; 283: 1967-75.
3. Talseth T, Westlie L, Daae L. Doxazosin nand atenolol as monotherapy on mild and moderate hypertension: a randomized parallel study with a three-year follow up. Am Heart J. 1991; 121(suppl): 280-5.
4. Giorda C, Appendina M, Mason MG et al. Alpha1-blocker doxazosin inproves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism. 1995; 44: 673-6.
5. Ramsay LE, Williams B, Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999; 13: 569-92.
6. Maruenda J, Bhatnagar V, Lowenthal DT. Hypertension in the elderly with coexisting benign prostatic hyperplasia. Urology. 1999; 53(suppl 3a): 7-13.
7. Cybulska B, Szostak WB. Postępowanie w zaburzeniach lipidowych u chorego na nadciśnienie tętnicze. Przewodnik Lekarza. 2003; 1: 82-93.
8. Januszewicz W, Prejbisz A. Leczenie nadciśnienia tętniczego u chorych ze współistniejącymi zaburzeniami metabolicznymi. Nefrol Nadciśn Tętn. 2005.
9. Poulter N, Williams B. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Am J Hypertens. 2001; 14: 1170-2.
10. Ferrara La, di Marino L, Russo O et al. Doxazosin and Captopril in Mildly Hypercholesterolemic Hypertensive Patients – The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; (21): 97-104.
11. Borgsteede S, Bruggeman R, Hoefnagel R et al. Tamsulosin and hyperglycaemia in patients with diabetes. Neth J Med. 2010; 68(3): 141-3.
12. Hutchinson DS, Bengtsson T. Alpha1A-adrenoceptors activate glucose uptake in L6 muscle cells through a phospholipase C-, phosphatidylinositol- 3 kinase-, and atypical protein kinase C-dependent pathway. Endocrinol. 2005; 146(2): 901-12.
13. Cheng JT, Liu IM, Yen ST et al. Role of alpha1A-adrenoceptor in the regulation of glucose uptake into white adipocyte of rats in vitro. Auton Neurosci. 2000; 84(3): 140-6.
14. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int. 2003; 91: 41-4.
15. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005; 31: 664-73.
16. Irini P, Chatziralli MD, Theodoros N et al. Risk Factors for Intraoperative Floppy Iris Syndrome: a Meta-Analysis. Ophthalmology. 2011; 118: 730-5.
17. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97(2): 34-8.
18. Lepor H; for the Tamsulosin Investigator Group. Phase III multicenter placebo‐controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998; 51: 892-900.
19. Lepor H; for the Tamsulosin Investigator Group. Long‐term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled double‐blind extension of phase III trial. Urology. 1998; 51: 901-6.
20. Narayan P, Lepor H. Long‐term open‐label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001; 57: 466-70.
21. Chung MS, Lee SH, Parket KK et al. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. Int J Clin Pract. 2011; 65(11): 1193-9.
22. Zhang K, Yu W, Jin J et al. Effect of Doxazosin Gastrointestinal Therapeutic System 4 mg vs Tamsulosin 0.2 mg Nocturia in Chinese Men With Lower Urinary Tract Symptoms: a Prospective, Multicenter, Randomized, Open, Parallel Study. Urology. 2011; 78(3): 636-40.